Sepha embarks on a busy Spring of International Exhibitions
April 6, 2016Medical Communications sepha, spring
Pharmaceutical packaging specialist, Sepha Ltd, has sprung into the spring quarter with a number of international exhibitions. Having developed a …
Allergan, Pfizer confirm termination of $160 billion merger
April 6, 2016Business Services, Research and Development, Sales and Marketing
Botox maker Allergan Plc (NYSE:AGN) and US pharma giant Pfizer (NYSE: PFE) on Wednesday confirmed they have terminated the merger …
Sun to cut jobs in Irish facility closure; Lilly announce further investment in the country
April 6, 2016Manufacturing and Production, Research and Development Eli Lilly, Ireland, Kinsale, Sun Pharma, cashel, investment, lilly
There was mixed news for pharmaceutical manufacturing in Ireland as Sun Pharma announced its decision to close its facility based …
Celltrion’s biosimilar for J&J’s arthritis drug gets UF FDA okay
April 6, 2016Manufacturing and Production, Research and Development
Korea-based Celltrion (Kosdaq: 068270) has received US regulatory approval for its biosimilar version of the arthritis drug marketed by Johnson …
Pfizer to call off $160 billion merger with Allergan
April 6, 2016Business Services, Research and Development, Sales and Marketing Allergan, Pfizer, deal, legal, merger and acquisition, regulation
US pharma giant Pfizer Inc (NYSE: PFE) has decided to terminate the $160 billion merger with Botox-maker Allergan Plc (NYSE: …
Phase III trial initiated in Merck and Pfizer partnership for renal cell carcinoma drug
April 6, 2016Research and Development Merck, Pfizer, avelumab, carcinoma, inlyta, javelin, partnership, phase III, renal
The first patient has been treated in the Phase III clinical trial, which sees Merck (ETR: MRK) and Pfizer (NYSE: …
Merck receives CE Mark approval for new liquid biopsy test for colorectal cancer
April 6, 2016Medical Communications, Research and Development, Sales and Marketing CE Mark, Merck, biomarker, biopsy, colorectal cancer, liquid biopsy, ras, sysmex inostics
Merck (ETR: MRK) has announced that their new liquid biopsy RAS biomarker test for metastatic colorectal cancer, developed in collaboration …
EMVO appoints new general manager
April 5, 2016Medical Communications andreas walter, emvo
The European Medicines Verification Organisation (EMVO), the body established to implement the European Falsified Medicines Directive and the Delegated Regulation, …
Valeant’s ad hoc committee closes chapter on Philidor controversy
April 5, 2016Medical Communications, Research and Development, Sales and Marketing Philidor, Valeant, ad hoc, ad hoc committee
Valeant (NYSE: VRX) has announced that the ad hoc committee of the board of directors has finished its review of …
Pfizer’s tofacitinib shows promise for psoriatic arthritis treatment in Phase III trial
April 5, 2016Medical Communications, Research and Development, Sales and Marketing Allergan, Pfizer, Xeljanz, merger, phase III, psoriatic arthritis, tofacitinib
Pfizer has announced positive top-line results from their latest Phase III study investigating Xeljanz (tofacitinib citrate). The OPAL Broaden trial …
Samsung Bioepis takes AbbVie to court over attempts to delay Humira biosimilars
April 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, Biogen, Humira, Samsung Bioepis, biosimilars, rheumatoid arthritis
Samsung Bioepis has filed a lawsuit against Abbvie (NYSE: ABBV) to stop the maker of the world’s bestselling drug Humira …
Flexion Therapeutics announce results for Zilretta trials in osteoarthritis pain
April 5, 2016Manufacturing and Production, Research and Development drugs, flexion, flexion therapeutics, osteoarthritis, pipeline, treatments, zilretta
Flexion Therapeutics has presented positive results from two pivotal clinical trials for its lead drug candidate, Zilretta, which show that …
FDA approves Gilead’s latest HIV treatment
April 5, 2016Manufacturing and Production, Research and Development Gilead, HIV, descovy, taf, taf-based, therapy
Gilead (NASDAQ: GILD) has announced that the US Food and Drug Administration has approved their TAF-based HIV therapy, Descovy (emtricitabine, …
Gilead to buy Nimbus Therapeutics’ unit, trial drug for up to $1.2 billion
April 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Gilead Sciences, M&A, MA, Nimbus Apollo, Nimbus Therapeutics, merger and acquisitions
Gilead Sciences (Nasdaq: GILD) has agreed to buy a unit of biotechnology firm Nimbus Therapeutics and its trial drug to …
Janssen and Genmab sued for patent infringement in US
April 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Genmab, Janssen, darzalex, morphosys, patent infringement
German biotech company, Morphosys, is suing Janssen and Genmab for alleged patent infringement in their oncology drug, Darzalex (daratumumab).
Outsourcing and Robots: how smart pharmas are optimising R&D operations
April 5, 2016Manufacturing and Production
Faced with steadily rising research and development costs, as well as increasingly stringent regulatory requirements, pharmaceutical firms are re-evaluating their …
Anika Therapeutics names CMO, COO
April 4, 2016Sales and Marketing Anika Therapeutics, CMO, COO, Executive appointment
Anika Therapeutics (Nasdaq: ANIK) on Monday named the executive appointments of Stephen Mascioli the chief medical officer (CMO) and Dana …
Eisai’s Halaven recommended for European approval
April 4, 2016Research and Development, Sales and Marketing Eisai, Halaven, liposarcoma
Eisai has received a positive opinion from the European Commission’s CHMP for Halaven (eribulin) as a second-line therapy for patients …
Weekly Movers: Lupin, Natco Pharma, Keryx, Puma Biotech
April 4, 2016Research and Development, Sales and Marketing
Another week of big gains and some major losses has come to pass. While the Indian pharma sector continues to …
Research shows Novartis’s Entresto reduces cardiovascular death and heart failure
April 4, 2016Research and Development, Sales and Marketing Entresto, Novartis, Regeneron, Sanofi, cardiovascular, clinical trial, patent
Novartis has announced results from the PARADIGM-HF clinical trial that show that Entresto (sacubitril/valsartan) consistently demonstrated benefit among heart failure …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
